The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing

Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acut...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunbar, Hazel, Weiss, Daniel J, Rolandsson Enes, Sara, Laffey, John G, English, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616504/
https://www.ncbi.nlm.nih.gov/pubmed/34831203
http://dx.doi.org/10.3390/cells10112982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616504/
https://www.ncbi.nlm.nih.gov/pubmed/34831203
http://dx.doi.org/10.3390/cells10112982

Ejemplares similares